Advertisement
"Despite of the short treatment period we were surprised to see thatanalysis of induced sputum prior to and after Bimosiamose treatment of 9 daysshowed that both relative and absolute lymphocytes count decreasedsignificantly. In addition, sputum IL-8 was significantly decreased. Thelatter is supposed to correlate with the severity of the disease," commentedProf. Dr. Meyer-Sabellek, clinical advisor to Revotar and previously SVPResearch&Development at AstraZeneca, Germany. "Inhalation of Bimosiamosetwice daily for up to 9 days was well tolerated and safe in patients. Thistargeted therapy provides the potential to prevent the further progression ofinflammatory components in COPD and should be evaluated further in largerclinical trials," added Prof. Dr. Witt from the Charite and the PrincipalInvestigator of the study.
Advertisement
About COPD
Chronic Obstructive Pulmonary Disease (COPD) comprises many seriousconditions affecting the lung. More than 30 million people are living withCOPD worldwide. COPD is the fourth leading cause of death and is responsiblefor more than 120,000 deaths a year in the US and Western Europe alone. Thedisease costs the US healthcare system US$40 billion per year.
About Revotar Biopharmaceutical AG
Revotar develops innovative anti-inflammatory drugs for inflammatoryindications such as psoriasis, chronic obstructive pulmonary disease (COPD)and acute lung injury (ALI). Bimosiamose has already passed several clinicalPhase I and Phase IIa trials in asthma and psoriasis with a good safety andefficacy profile in over 140 human beings. In summer 2006 Revotar announcedthe signing of a Start-Up Development Agreement with a US Pharma company forthe further development of Bimosiamose in one major disease area. Revotarwill present during the BioEurope conference in Hamburg on November 14, 2007.Contact Address: Stephan Tarlach Executive Board Revotar Biopharmaceuticals AG Neuendorfstr. 24a D-16761 Hennigsdorf phone: +49-3302-2025040 fax: +49-3302-2025030 e-mail: [email protected] http://www.revotar.de
SOURCE Revotar Biopharmaceutics AG
